2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Serologic Tests, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4057 Longitudinal serum mass spectrometry in the GEM2017FIT trial dynamically updates progression risk beyond bone marrow MRD in fit older patients with multiple myeloma

Noemi Puig, PhD, Cristina Agullo, MD, PhD2, Bruno Paiva, PhD3, Maria Teresa Cedena Romero, MD4, Sergio Castro, MSc5, Anna Maria Sureda Balari, MD,PhD6, Albert Oriol Sr, MD7, Enrique Ocio Sr, MD, PhD8, Laura Rosiñol Dachs Sr, MD, PhD9, Esther González García10, Sebastián Garzón11, María-Jesús Blanchard, MD12, Alexia Suarez Cabrera, MD13, Luis Felipe Casado Montero, MD, PhD14, Joaquin Martinez-Lopez Sr, MD, PhD15, Yolanda González-Montes, MD16, Miguel Teodoro Hernández Garcia17, Joan Bargay, MD, PhD18, Ana-Isabel Teruel19, Mercedes Gironella Mesa, MD20, Jaime Perez de Oteyza, MD, PhD21, Valentin Cabanas Perianes, MD22, Angel Ramirez23, Pilar Delgado24, Elena Prieto25, Virginia Fernandez-Chanca26, Paula Sanchez-Garcia27, Borja Puertas, MD, PhD28, Joan Batista Blade Creixenti Sr, MD29, Juan-Jose Lahuerta Palacios, MD, PhD30, Jesus San-Miguel Sr, Md, PhD31, Maria-Victoria Mateos Jr, MD, PhD32
1 Department of Hematology, University Hospital of Salamanca, IBSAL, IBMCC-CSIC, CIBERONC, Salamanca, Spain
2 Clinical Laboratory, University Hospital of Salamanca, Salamanca, Spain
3 Centre for Applied Medical Research, Cancer Center Clinica Universidad de Navarra, University of Navarra, IdiSNA, CIBERONC, Navarra, Spain
4 Hospital Universitario 12 de Octubre, CIBER-ONC CB16/12/00369, CNIO, Madrid, Spain
5 Clinical Laboratory, University Hospital of Salamanca, Salamanca, Spain
6 Institut Català d’Oncologia-Hospitalet, IDIBELL, Barcelona, Spain
7 Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Barcelona, Spain
8 Hospital Universitario Marques de Valdecilla, IDIVAL, Universidad de Cantabria, Santander, Spain
9 Hospital Clinic, Barcelona, Spain
10 Hospital Universitario de Cabueñes, Asturias, Spain
11 Hospital Jerez de la Frontera, Cadiz, Spain
12 Hospital Ramón y Cajal, Madrid, Spain
13 Hospital Universitario de Gran Canaria Doctor Negrín, Gran Canaria, Spain
14 Hospital General Universitario de Toledo, Toledo, Spain
15 Hospital Universitario 12 de octubre, Universidad Complutense, CNIO, Madrid, Spain
16 Institut d'Oncologia Dr. Josep Trueta, Girona, Spain
17 Hospital Universitario de Canarias, Canarias, Spain
18 Hospital Universitario Son LLatzer, Mallorca, Spain
19 Hospital Clínico de Valencia, Valencia, Spain
20 Hospital Universitario Vall d´Hebron, Barcelona, Spain
21 Hospital Universitario HM Sanchinarro, Madrid, Spain
22 Department of Hematology, IMIB-Virgen de la Arrixaca University Hospital. University of Murcia, Murcia, Spain
23 Hospital Central de Asturias, Asturias, Spain
24 Hospital Universitario Lozano Blesa, IIS Aragón, Zaragoza, Spain
25 Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
26 Clinical Laboratory, University Hospital of Salamanca, Salamanca, Spain
27 Clinical Laboratory, University Hospital of Salamanca, Salamanca, Spain
28 Department of Hematology, University Hospital of Salamanca, IBSAL, IBMCC-CSIC, CIBERONC, Salamanca, Spain
29 Hospital Clinic, Barcelona, Spain
30 Hospital Universitario 12 de Octubre, CIBER-ONC CB16/12/00369, CNIO, Madrid, Spain
31 Centre for Applied Medical Research, Cancer Center Clinica Universidad de Navarra, University of Navarra, IdiSNA, CIBERONC, Navarra, Spain
32 Department of Hematology, University Hospital of Salamanca, IBSAL, IBMCC-CSIC, CIBERONC, Salamanca, Spain

Background: Bone marrow (BM) measurable residual disease (MRD) is strongly prognostic in multiple myeloma (MM), but a single-site assessment cannot capture subsequent disease kinetics. Serial serum mass spectrometry (MS) provides a minimally invasive opportunity to update risk over time. We investigated whether each current MS result adds clinically relevant prognostic information to post-treatment BM MRD in fit older patients enrolled in GEM2017FIT.

Methods: Patients aged 65–80 years with newly diagnosed MM and evaluable BM MRD after cycle 18 (post-C18) were included. Time zero was the post-C18 MRD date, and progression-free survival (PFS) was measured from that date to progression or death. BM MRD by next-generation flow at 10-5 was modeled as a fixed baseline covariate. Serum monoclonal proteins were assessed thereafter by quantitative immunoprecipitation MS using EXENT. MS status was updated on the actual date of each determination. A multivariable start-stop Cox model included trial treatment group, cytogenetic class (high risk, defined by del(17p), t(4;14), or t(14;16); isolated t(11;14); or other), post-C18 BM MRD, and time-updated MS status, with robust standard errors clustered by patient. Secondary analyses evaluated positive-state kinetics, pooled landmarks at months 3, 6, 9, 12, 18, 24, and 36 to estimate PFS during the subsequent 6 months, and the incremental discrimination provided by each new MS result.

Results: Overall, 261 patients were included; median age was 72.8 years (IQR, 70.7–75.6), 123 (47.1%) were male, and isotype was IgG in 152 (58.2%), IgA in 68 (26.1%), light-chain-only in 37 (14.2%), and other in 4 (1.5%). At post-C18, 166 patients (63.6%) were BM MRD-negative and 95 (36.4%) were MRD-positive at 10?5. During follow-up, 88 PFS events occurred. Overall, 783 serum MS determinations (227 positive and 556 negative) were available from 196 patients.

In the multivariable time-dependent model, post-C18 BM MRD positivity was associated with inferior PFS (adjusted HR [aHR], 2.00; 95% CI, 1.15–3.48; P=.014). Independently of treatment group, cytogenetic class, and BM MRD, a positive MS result was associated with a markedly higher risk of progression or death than a negative result (aHR, 5.16; 95% CI, 2.84–9.37; P<.001). Updated MS status significantly improved the baseline model (likelihood-ratio χ²=34.61; 2 df; P<.001). This improvement was driven by the positive/negative MS result rather than by whether a post-C18 sample was available, because a time-updated indicator of sample availability was not associated with PFS (P=.849). The effect was stable across 500 patient-level bootstrap samples and leave-one-patient-out analyses (HR range, 4.94–5.59).

Negative-to-positive conversion identified the highest-risk positive state (aHR vs current MS negativity, 8.23; 95% CI, 4.38–15.46; P<.001) and carried greater risk than persistent positivity (HR, 2.34; 95% CI, 1.08–5.10; P=.032). However, detailed kinetic categories did not conclusively improve model fit over current positive/negative status (P=.067) and remain exploratory. In the pooled landmark analysis, a positive MS result predicted progression or death within the subsequent 6 months (aHR, 3.98; 95% CI, 1.46–10.88; P=.007). At each reassessment, 6-month risk discrimination was evaluated immediately before and after adding the new MS result to all previously available information. The new result increased the AUC by a median absolute 0.097 (95% CI, 0.041–0.172), with improvement in 99.8% of bootstrap replicates, demonstrating incremental prognostic information from each new determination.

Conclusions: Serial serum MS provides dynamic prognostic information beyond post-C18 BM MRD, treatment group, and cytogenetic risk. The latest positive/negative result is a simple, clinically interpretable marker that updates near-term risk, while negative-to-positive conversion may identify a particularly high-risk state. These findings support integrating serial serum MS with BM-based MRD monitoring in patients with MM.

Noemi Puig, PhD: Amgen - Honoraria; Sanofi - Honoraria; BMS - Honoraria; GSK - Honoraria; BD/Waters - Honoraria; Regeneron - Honoraria; Menarini - Honoraria; Kite - Honoraria; Thermofisher - Honoraria; Johnson & Johnson - Honoraria; Abbvie - Honoraria; PFIZER - Honoraria; Oncopeptides - Honoraria; Takeda - Honoraria; PFIZER - Research Funding; Amgen - Research Funding; Thermofisher - Research Funding; Takeda - Research Funding; Johnson & Johnson - Research Funding; BMS - Research Funding; GSK - Research Funding; Johnson & Johnson - Consultancy (Includes expert testimony); Menarini - Consultancy (Includes expert testimony); Thermofisher - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Oncopeptides - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); PFIZER - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); BD/Waters - Consultancy (Includes expert testimony)